Melancholic symptoms in bipolar II depression and responsiveness to lamotrigine in an exploratory pilot study

Journal of Clinical Psychopharmacology

Volumn 38, Issue 5, 2018, Pages 509-512

  Peters, Evyn M ^a   Bowen, Rudy ^a   Balbuena, Lloyd ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

bipolar disorder; lamotrigine; melancholic depression; personalized medicine

Indexed keywords

LAMOTRIGINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BIPOLAR DISORDER; DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LAMOTRIGINE; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 85053216421     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000947     Document Type: Article

References (24)

1. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194:4-9.
2. Geddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): A 2- 2 factorial randomised trial. Lancet Psychiatry. 2016;3:31-39.
3. Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013;74:675-684.
4. Juruena MF, Bocharova M, Agustini B, et al. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. J Affect Disord. 2018;233:45-67.
5. Korte SM, Prins J, Krajnc AM, et al. The many different faces of major depression: It is time for personalized medicine. Eur J Pharmacol. 2015; 753:88-104.
6. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015;20:32-47.
7. Makatsori A, Duncko R, Moncek F, et al. Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine. Neuroendocrinology. 2004;79:34-42.
8. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426-437.
9. Brown ES, Wolfshohl J, Shad MU, et al. Attenuation of the effects of corticosteroids on declarative memory with lamotrigine. Neuropsychopharmacology. 2008;33:2376-2383.
10. Brown ES, Zaidel L, Allen G, et al. Effects of lamotrigine on hippocampal activation in corticosteroid-treated patients. J Affect Disord. 2010;126: 415-419.
11. Desai S, Khanani S, ShadMU, et al. Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy. J Clin Psychopharmacol. 2009;29:284-287.
12. GlaxoSmithKline. A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder [GSK Clnical Study Register]. 2016. Available at: Https:// www.gsk-clinicalstudyregister.com/study/SCA100223. Accessed May 28, 2018.
13. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IVAxis I Disorders Research Version (SCID-I). NewYork:Biometric Research, New York State Psychiatric Institute; 1996.
14. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355: 1064-1069.
17. Burke JF, Sussman JB, Kent DM, et al. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351:h5651.
18. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl JMed. 2007;357: 2189-2194.
19. Valerio MP, Szmulewicz AG, Martino DJ. A quantitative review on outcome-to-antidepressants in melancholic unipolar depression. Psychiatry Res. 2018;265:100-110.
20. GiliM, RocaM, Armengol S, et al. Clinical patterns and treatment outcome in patients with melancholic, atypical and non-melancholic depressions. PloS ONE. 2012;7:e48200.
21. Mitchell PB, Malhi GS. Bipolar depression: Phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6:530-539.
22. Bowen RC, Balbuena L, Baetz M. Lamotrigine reduces affective instability in depressed patients with mixed mood and anxiety disorders. J Clin Psychopharmacol. 2014;34:747-749.
23. Zavodnick AD, Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: A literature review. Psychiatry Q. 2012;83: 371-383.
24. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27:173-184.